Viracta Therapeutics Inc (NASDAQ: VIRX) on Friday, soared 8.78% from the previous trading day, before settling in for the closing price of $0.24. Within the past 52 weeks, VIRX’s price has moved between $0.20 and $1.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 134.94%. The company achieved an average annual earnings per share of 32.07%. With a float of $27.71 million, this company’s outstanding shares have now reached $39.09 million.
Considering the fact that the conglomerate employs 40 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 38.08%, operating margin of -6707.32%, and the pretax margin is -6143.09%.
Viracta Therapeutics Inc (VIRX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Viracta Therapeutics Inc is 29.69%, while institutional ownership is 21.82%. The most recent insider transaction that took place on Feb 27 ’24, was worth 2,493. In this transaction CFO and COO of this company sold 3,405 shares at a rate of $0.73, taking the stock ownership to the 102,306 shares. Before that another transaction happened on Nov 30 ’23, when Company’s President and CEO bought 52,094 for $0.49, making the entire transaction worth $25,734. This insider now owns 52,094 shares in total.
Viracta Therapeutics Inc (VIRX) Earnings and Forecasts
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.33 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.3) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 32.07% per share during the next fiscal year.
Viracta Therapeutics Inc (NASDAQ: VIRX) Trading Performance Indicators
Viracta Therapeutics Inc (VIRX) is currently performing well based on its current performance indicators. A quick ratio of 1.08 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.16, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -0.66 in one year’s time.
Technical Analysis of Viracta Therapeutics Inc (VIRX)
Compared to the last year’s volume of 0.3 million, its volume of 1.26 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 73.07%. Additionally, its Average True Range was 0.02.
During the past 100 days, Viracta Therapeutics Inc’s (VIRX) raw stochastic average was set at 10.03%, which indicates a significant decrease from 59.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.22% in the past 14 days, which was lower than the 90.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2387, while its 200-day Moving Average is $0.5898. Nevertheless, the first resistance level for the watch stands at $0.2938 in the near term. At $0.3237, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.3501. If the price goes on to break the first support level at $0.2375, it is likely to go to the next support level at $0.2111. Should the price break the second support level, the third support level stands at $0.1812.
Viracta Therapeutics Inc (NASDAQ: VIRX) Key Stats
Market capitalization of the company is 10.41 million based on 39,272K outstanding shares. Right now, sales total 0 K and income totals -51,060 K. The company made 0 K in profit during its latest quarter, and -9,830 K in sales during its previous quarter.
